T‑Bren

N/A

Report date: 2026/05/26 20:00:28

Base Information

Drug NameT‑Bren
Drug Alias NameHER2 ADCBLM07D1BL-M07D1
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > Cleavable peptide linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Ed-04 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-HER2
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursUterine Cervical Neoplasms +[19] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesSystImmuneSichuan Baili Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBaili-Bio (Chengdu) Pharmaceutical Co LtdSystImmuneSichuan Baili Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursUterine Cervical Neoplasms +[19] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A